Flutiform fluticasone/formoterol: Phase III started

Kyorin began an open-label, Japanese Phase III trial to evaluate twice-daily 100/10, 250/10 and 500/10 µg doses of Flutiform fluticasone/formoterol for 52 weeks in adult asthmatics. An MAA for Flutifo...